Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III RenalCell Carcinoma. Journal of Kidney Cancer, [S. l.], v. 13, n. 2, p. 21–28, 2026. DOI: 10.15586/jkcvhl.v13i2.455. Disponível em: https://www.jkcvhl.com/index.php/jkcvhl/article/view/455. Acesso em: 4 jun. 2026.